Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has provided an announcement.
Artrya Limited announced the issuance of securities including 1,300,000 ordinary shares, 756,659 performance rights, and 303,333 restricted stock units under its employee incentive plan. This move is part of Artrya’s strategy to incentivize its workforce and align their interests with the company’s goals, potentially enhancing its operational capabilities and market positioning in the medical technology sector.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.87 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited (ASX: AYA) is an Australian medical technology company focused on developing AI-powered solutions to enhance the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient patient diagnoses. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 272,701
Technical Sentiment Signal: Buy
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.